EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieMultizentrische StudieOpen Access

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth iD, Richard G Moore iD, Mariusz Bidziński, Sandro Pignata iD, Ali Ayhan, M Jesús Rubio iD, Mario Beiner, Marcia Hall iD, Christof Vulsteke iD, Elena Ioana Braicu iD, Kenzo Sonoda iD, Xiaohua Wu iD und 19 weitere

Journal of Clinical Oncology · 20.03.2025 · 43 (9) · 1083-1100

DOI: 10.1200/jco-24-01326 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2025. Verfasst von Christian Marth und 30 weiteren Autor:innen. Beteiligte Einrichtung: AGO-Austria and Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) in the phase III Study 309/KEYNOTE-775. We report results from the phase III, randomized, open-label European Network of Gynaecological Oncological Trial-en9/LEAP-001 study (ClinicalTrials.gov identifier: NCT03884101 ) that evaluated len + pembro versus chemotherapy in first-line aEC. METHODS Patients with stage III to IV or recurrent, radiographically apparent EC and no previous chemotherapy or disease progression ≥6 months after neo/adjuvant platinum-based chemotherapy were randomly assigned 1:1 to lenvatinib 20 mg once daily plus pembrolizumab 200 mg once every 3 weeks or paclitaxel 175 mg/m 2 plus carboplatin AUC 6 mg/mL/min once every 3 weeks. Primary end points were PFS and OS, evaluated in the mismatch repair-proficient (pMMR) and all-comers populations. Noninferiority was assessed for OS at final analysis (FA) for len + pembro versus chemotherapy (multiplicity-adjusted, one-sided nominal alpha, .0159; null hypothesis–tested hazard ratio [HR], 1.1). RESULTS Eight hundred forty-two patients were randomly assigned (len + pembro, n = 420 [pMMR population, n = 320]; chemotherapy, n = 422 [pMMR population, n = 322]). At FA (data cutoff, October 2, 2023), median PFS (95% CI) in the pMMR population was 9.6 (8.2 to 11.9) versus 10.2 (8.4 to 10.5) months with len + pembro versus chemotherapy (hazard ratio [HR], 0.99 [95% CI, 0.82 to 1.21]) and among all-comers was 12.5 (10.3 to 15.1) versus 10.2 (8.4 to 10.4) months (HR, 0.91 [95% CI, 0.76 to 1.09]; descriptive analyses). Median OS (95% CI) in the pMMR population was 30.9 (25.4 to 37.7) versus 29.4 (26.2 to 35.4) months with len + pembro versus chemotherapy (HR, 1.02 [95% CI, 0.83 to 1.26]; noninferiority P = .246, not statistically significant per multiplicity control strategy) and among all-comers was 37.7 (32.2 to 43.6) versus 32.1 (27.2 to 35.7) months (HR, 0.93 [95% CI, 0.77 to 1.12]). Grade ≥3 treatment-related adverse events occurred in 331/420 (79%) versus 274/411 (67%) treated patients. CONCLUSION First-line len + pembro did not meet prespecified statistical criteria for PFS or OS versus chemotherapy in pMMR aEC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsEndometrial NeoplasmsPhenylurea CompoundsQuinolinesAdultAgedAged, 80 and overFemaleHumansMiddle AgedCarboplatinPaclitaxelProgression-Free Survival

Substanzen

Antibodies, Monoclonal, HumanizedCarboplatinlenvatinibPaclitaxelpembrolizumabPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • AGO-Austria and Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester, Rochester, NY.
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Warsaw, Poland.
  • Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
  • Turkish Society of Gynecologic Oncology (TRSGO), Başkent University, Ankara, Turkey.
  • Deceased.

ORCID-Profile: Christian Marth, Richard G Moore, Sandro Pignata, M Jesús Rubio, Marcia Hall, Christof Vulsteke, Elena Ioana Braicu, Kenzo Sonoda, Xiaohua Wu, André Mattar, Stephanie Lheureux, Xiaojun Chen, Kosei Hasegawa, Manuel Magallanes-Maciel, Peng-Hui Wang, Regina Berger, Chinyere E Okpara, Jodi McKenzie, Lucy Gilbert, Vicky Makker

Förderung

  • NCI NIH HHS

Zitieren

APA

Marth, C., Moore, R. G., Bidziński, M., Pignata, S., Ayhan, A., Rubio, M. J., Beiner, M., Hall, M., Vulsteke, C., Braicu, E. I., Sonoda, K., Wu, X., Frentzas, S., Mattar, A., Lheureux, S., Chen, X., Hasegawa, K., Magallanes-Maciel, M., Choi, C. H., …, & ENGOT-en9/LEAP-001 Investigators (2025). First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 43(9), 1083-1100. https://doi.org/10.1200/jco-24-01326

Vancouver

Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, et al. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 2025;43(9):1083-1100. doi:10.1200/jco-24-01326

BibTeX
@article{Marth2025,
  author = {Marth, Christian and Moore, Richard G and Bidziński, Mariusz and Pignata, Sandro and Ayhan, Ali and Rubio, M Jesús and Beiner, Mario and Hall, Marcia and Vulsteke, Christof and Braicu, Elena Ioana and Sonoda, Kenzo and Wu, Xiaohua and Frentzas, Sophia and Mattar, André and Lheureux, Stephanie and Chen, Xiaojun and Hasegawa, Kosei and Magallanes-Maciel, Manuel and Choi, Chel Hun and Shalkova, Mariia and Kaen, Diego and Wang, Peng-Hui and Berger, Regina and Okpara, Chinyere E and McKenzie, Jodi and Yao, Lili and Orlowski, Robert and Khemka, Vivek and Gilbert, Lucy and Makker, Vicky and ENGOT-en9/LEAP-001 Investigators, ENGOT-en9/LEAP-001 Investigators},
  title = {First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {9},
  pages = {1083--1100},
  doi = {10.1200/jco-24-01326}
}
Kostenlos starten →